INTRODUCTION
============

Chronic myeloid leukemia (CML) has been considered as one of the essential neoplastic aberration directly linked to a genetic disorder. CML is a three-phase disease. Most of the patients diagnosed with CML are in a chronic phase (CP) with \< 10% myeloblasts in the bone marrow (BM) and blood. Untreated CML-CP invariably transforms into blastic phase (BP) resembling acute myeloid and lymphoid leukemia with \> 20% myeloblasts in the bone marrow and peripheral blood. Intermediate phase, named accelerated phase, is defined with 10% to 20% myeloblasts.[@b1-jcp-22-074] The karyotype mark of CML is Philadelphia (Ph^1^) chromosome,[@b2-jcp-22-074] which is a result of chromosomal rearrangement, t(9:22) (q^34^:q^11^).[@b3-jcp-22-074] Aberrant BCR-ABL1 fusion protein constitutively activates downstream enzymes which enhance growth factor-independent proliferation, reprogramed adhesion, and resistance to DNA repair. The transcription of *BCR-ABL* and the resulting fusion protein is a key target and biomarker in the treatment and monitoring of CML ([Fig. 1](#f1-jcp-22-074){ref-type="fig"}). The targeting of BCR-ABL fusion kinase is the prime novel paradigm of molecularly targeted therapy. Tyrosine kinase inhibitors (TKIs) that specifically inhibit BCR-ABL signaling activity by competing for ATP may revolutionize the treatment of CML.[@b4-jcp-22-074]

The tyrosine kinase activated by fusion changes the levels of enzyme phosphorylation and inhibits cellular apoptosis, which are essential for initiating malignancy. TKI effectively inhibits the activity of the BCR-ABL1 proteins in patients with CML by attaching to the ATP-binding pocket of tyrosine kinase[@b5-jcp-22-074] and managing minimal residual disease and target relapse after curing.[@b6-jcp-22-074] Responses to TKI therapy are determined with changes in BCR-ABL fusion protein.

ELEMENTS TO DETECT BCR-ABL1 GENE AND PROTEIN
============================================

The detection of *BCR-ABL1* and its product has been achieved through a series of development from karyotyping to cellular and molecular genetics. However, its sensitivity is not sufficient to diagnose total chromosomal aberration. In contrast, immunologic methods are useful to diagnose the onco-protein in peripheral blood specimen based on antibody-antigen binding. The labeled antibodies bind to fusion proteins and the signals are detected by colorimetric and flow cytometric analyses to measure fusion amino acid.[@b7-jcp-22-074]

CYTOGENETIC ANALYSIS
====================

Cytogenetic method shows metaphase stage by banding methods that subdivide each interphase into many of alternating white and black bands.[@b8-jcp-22-074] The bone marrow specimen from individual was cultured to obtain metaphase in the slide. After specific staining procedure (e.g., Giemsa, quinacrine mustard), the arrangement of metaphases can be visualized with a fluorescence microscope.

Fluorescence in situ hybridization (FISH) can detect cells in metaphase or interphase, and specimens can derive from bone marrow, peripheral blood, and other specimen. These probes are fluorochrome-labeled and the detected signals are observed with a fluorescence microscope.[@b9-jcp-22-074] Normally, there is red *BCR* signal (R) and green *ABL* signal (G) on the normal chromosomes 9 and 22, respectively. Compared with conventional cytogenetics, FISH needs less time to get results (often within 45 hours) and has high sensitivity to detect specific disorder.

NATIONAL COMPREHENSIVE CANCER NETWORK GUIDELINES ON MONITORING FREQUENCIES
==========================================================================

The National Comprehensive Cancer Network (NCCN) ([Table 1](#t1-jcp-22-074){ref-type="table"}) has provided and updated guidelines for the frequencies of molecular monitoring in patients treated with TKIs.

1. Molecular methods
--------------------

PCR is used widely to measure *BCR-ABL1* mRNA for its high sensitivity and specificity. Total RNA is extracted from blood or BM and then reverse transcribed into cDNA using specific primers through PCR reaction.[@b10-jcp-22-074] If the first PCR reaction has nonspecific products, the products cannot be amplified in the second reaction. The specificity of *BCR-ABL1* diagnostic assays could be enhanced by nested primers. PCR products are observed by agarose gel electrophoresis to identify whether *BCR-ABL* transcripts are detectable.

2. Somatic mutations in epigenetic regulators
---------------------------------------------

Some mutations in the genes of epigenetic regulators, ASXL1, TET2, TET3, KDM1A, and MSH6 were found in 25% of patients. DNA methylation has reported to be associated with pathogenesis of CML.[@b9-jcp-22-074] Three loss-of-function mutations (frameshift insertion, deletion, or nonsense mutation) found in *ASXL1* were existed within exon 12.[@b10-jcp-22-074]

ASXL1 has well-known functions in histone modification and plays a role as a putative tumor suppressor that is often reported to be mutated in hematological malignancies. In myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) patients, *ASXL1* mutations were concentrated within exon 12.[@b11-jcp-22-074],[@b12-jcp-22-074] Frameshift or nonsense mutations in exon 12 of *ASXL1* lead to the truncation of the protein and removal of the C-terminal, which contains a PHD finger that is a structural motif found in nuclear proteins and is involved in transcriptional regulation, chromatin modifications, and histone demethylation.[@b12-jcp-22-074]--[@b15-jcp-22-074]

TET2 initiates DNA demethylation and is frequently mutated in hematological malignancies, including CML.[@b16-jcp-22-074] *TET2* mutations in *JAK2* mutation-positive MPN patients clarify the effect of mutation order on disease phenotype and progression. KDM1A (also known as lysine-specific demethylase 1) is associated with the maintenance and differentiation of hematopoietic stem cells by demethylation of di- and tri-methylation of lysine 4 on histone 3.[@b17-jcp-22-074]

MSH6 is an essential component of the DNA mismatch repair mechanism.[@b18-jcp-22-074] Loss-of-function mutation was reported in relapsed ALL patients and the mutation leads to constitutional mismatch repair deficiency syndrome, which is characterized by the development of childhood cancers ([Table 2](#t2-jcp-22-074){ref-type="table"}), mainly hematological malignancies.[@b19-jcp-22-074] Taken together, epigenetic regulation may play important roles against the etiology of CML.

Recurrent somatic mutations in *COL7A1*, *CSMD2*, *CLSTN2*, and *DYSF* were also found in two patients. It has been reported that COL7A1 expression was significantly upregulated in cancer stem cells of solid tumors by the positive stimulation of TGF-β1 signaling.[@b20-jcp-22-074] TGF-β is a critical regulator of Akt activation in leukemia-initiating cells and controls FOXO3A localization in CML, which is responsible for maintaining leukemia-initiating cells.

3. Standardization of the multistep quantitative real time-PCR
--------------------------------------------------------------

For molecular testing results to become practical information that affects management decisions, it is imperative to standardize quantitative real time PCR (RT-qPCR) to permit comparison of individual laboratory results to the IRIS data and to enable clinical practice to follow NCCN guidelines.[@b5-jcp-22-074] RT-qPCR is a technically challenging multistep technique ([Fig. 2](#f2-jcp-22-074){ref-type="fig"}). Differences in sample collection, cell preparation, RNA isolation, reverse transcription, internal control selection, standard curve construction, and data reporting contribute to the outstanding variation found in the reported *BCR-ABL1* data.

4. Histopathology and immunohistochemistry
------------------------------------------

There is predominance of the granulocytic lineage, with dysgranulopoiesis as a defining feature of the disease. However, the presence of eosinophilia in the absence of *BCR-ABL1* transcripts should alert the pathologist for a possible rearrangement of PDGFRA, PDGFRB, or fibroblast growth factor receptor-1 overexpression. Bone marrow fibrosis may be present in up to 30% of patients with chronic myelomonocytic leukemia (CMML). The peripheral blood and bone marrow monocytes usually express CD33 and CD13, the typical antigens on myelocytes.

CHROMOSOMAL AND MOLECULAR ABNORMALITIEs
=======================================

No specific cytogenetic alterations have been identified in chromosome banding analysis of patients with CML. There has been an explosion in the discovery of several novel molecular abnormalities in patients with CMML. These can be divided into the following categories: (a) mutations in epigenetic control of transcription,[@b15-jcp-22-074],[@b21-jcp-22-074]--[@b25-jcp-22-074] such as histone modification (EZH2, ASXL1, and UTX), DNA methylation (TET2 and DNMT3A), or both (IDH1 and IDH2), (b) mutations in the spliceosome machinery (SF3B1, SRSF2, U2AF35 and U2AF65), (c) mutations in genes that regulate cytokine signaling (*JAK2*, *KRAS*, *NRAS*, *CBL*, and *FLT3*),[@b26-jcp-22-074]--[@b28-jcp-22-074] (d) mutations in transcription factors and nucleosome assembly (RUNX1 and SETBP1),[@b29-jcp-22-074]--[@b31-jcp-22-074] and (e) mutations in DNA damage response genes, such as *TP53*.[@b18-jcp-22-074] The relative frequency of these mutations in individuals with CMML is shown in [Table 2](#t2-jcp-22-074){ref-type="table"}. The most commonly identified abnormalities (approximately 40%--60% of all CMML patients) are mutations in *ASXL1*, *SRSF2*, and *TET2* genes. Mutations in *NRAS*, *CBL*, *IDH2*, *RUNX1*, *SETBP1*, and *SRSF2* have been shown to be predictors of poor outcome in univariable analysis. In contrast, mutations in the *ASXL1* gene have been shown to be significant in multivariable analysis.[@b32-jcp-22-074]

HEDGEHOG SIGNALING AND CANCER
=============================

The transition from the chronic to the advanced phase of CML involves distinct changes in gene expression that predict increased activation of the WNT/β-catenin pathway, as well as deregulated expression of several transcriptional regulators, including JunB, Fos, and PRAME.[@b18-jcp-22-074] Imatinib treatment has clearly improved the prognosis for CML patients, especially in the CP, the occurrence of relapse,[@b1-jcp-22-074],[@b2-jcp-22-074] resistance,[@b23-jcp-22-074],[@b33-jcp-22-074],[@b34-jcp-22-074] and the requirement for continued therapy.[@b35-jcp-22-074],[@b36-jcp-22-074] Here, we examine the stem cell origin of CML, and then discuss the recent findings that the Hedgehog (Hh) pathway contributes to the survival and expansion of *BCR-ABL* leukemic stem cells.[@b37-jcp-22-074],[@b38-jcp-22-074] Further analysis of patients resistant to imatinib led to the discovery of *BCR-ABL* amplifications and point mutations primarily located within the BCR-ABL kinase domain.

The Hh pathway, first discovered in the model organism Drosophila, functions in tissue patterning during embryonic development. In the absence of Hh ligands, the Patched (PTCH) receptor functions as an antagonist of the pathway by inhibiting the activation of Smoothened (SMO) ([Fig. 3](#f3-jcp-22-074){ref-type="fig"}). However, when Hh ligands bind PTCH, this effectively relieves repression on SMO, resulting in its activation. SMO activation culminates in a signal transduction cascade that causes the nuclear translocation of the GLI family of transcription factors (GLI1, 2, 3) and the subsequent induction of a distinct transcriptional regulatory program.

The role of the Hh pathway in post-natal hematopoeisis has been investigated using several experimental approaches. The expression of the two classical Hh target genes, *GLI1* and *PTCH1*, was assayed in CML patients, as in the murine BCR-ABL bone marrow transplant model. As a potential mechanism that leads to the upregulation of these Hh target genes in BCR-ABL positive cells, SMO expression was significantly upregulated at both the mRNA and protein levels. SMO overexpression appears to be primarily BCR-ABL independent. Imatinib treatment of BCR-ABL positive bone marrow cultures only led to a minor decrease in *Smo* and *Gli1* transcript levels. Therefore, it will be interesting to determine the precise mechanism that leads to SMO upregulation in BCR-ABL positive leukemic cells and whether this involves the interaction of leukemic cells with their microenvironment. Smo deficiency similarly decreased onset and latency of BCR-ABL-induced leukemia, and reduced frequency of leukemic stem cells (Lin^−^, Sca-1^+^, Kit^+^). Together, both these studies carry important implications for the application of Hh inhibition therapy in targeting the CML stem cell compartment. The critical molecular effectors downstream of activated Hh signaling in CML, however, will need further investigation. The contribution of additional Hh/ Gli targets, such as the proto-oncogenes, *BCL-2* and *CYCLIN D*, towards the growth of CML stem cells will need to be investigated.

BIOLOGICAL COMPLEXITY OF CHRONIC MYELOID LEUKEMIA
=================================================

The molecular mechanisms underlying cancer progression are still uncertain, but most likely involve activation of oncogenic factors and/or inactivation of tumor suppressors.[@b39-jcp-22-074] A plausible assumption is that BP is a multistep and time-dependent process initiated by both BCR-ABL1--dependent ([Fig. 4](#f4-jcp-22-074){ref-type="fig"}) and --independent DNA damage associated with inefficient and unfaithful DNA repair in CML-CP. CML-CP, if facilitated by an increased level of BCR-ABL1 activity, leads to selection of one or more CML-BP clones.

The relatively high BCR-ABL1 expression/activity in CML-CP CD34^+^CD38^−^ stem cells and/or CD34^+^ early progenitors compared with more committed progenitors, which is further markedly increased in CML-BP CD34^+^ progenitors, results in the following: enhancement of proliferation/survival pathways, increased genomic instability, activation of pathways blocking in myeloid differentiation, acquisition of the ability for self-renewing, and inhibition of tumor suppressors with broad cell regulatory functions.

The genetic lesions observed in CML-BP patients in the past and now since the introduction of TKIs mostly include the presence of additional chromosomes, gene deletions, gene insertions, and/or point mutations (including *BCR-ABL1* mutations),[@b40-jcp-22-074],[@b41-jcp-22-074] but patterns differ in myeloblastic and lymphoblastic transformations.

CONCLUSIONS
===========

There has been an increased understanding of several key genetic changes that drive CML. In this review, we described and critically evaluated different technologies used to detect *BCR-ABL1* transcripts in patients with CML. We focused on the comparison between current and new technologies. We discussed potential advantages of these new technologies for monitoring response to CML management. We suggest that molecular and NGS analyses may transform our approach to molecular monitoring of cancers in the next 5 to 10 years, not only for CML but also for other leukemias and solid cancers. In addition to analytical validation, the clinical relevance of better ability to detect and accurately quantify low levels of residual transcripts from cancer cells needs to be evaluated in clinical trials. The next challenge for investigators will be to bridge the gap between discoveries made in the laboratory, and identify novel therapies that target these molecular alterations to improve outcomes.
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![Schematic view of Philadelphia (Ph^1^) chromosome and *BCR-ABL1* fusion transcripts. (A) The Ph^1^ chromosome is the result of t(9;22)(q^34^:q^11^). (B) *BCR-ABL1* fusion transcripts with different breakpoints (<https://en.wikipedia.org/wiki/File:Schematic_of_the_Philadelphia_Chromosome.svg>).](jcp-22-074f1){#f1-jcp-22-074}

![The principal steps of the quantitative real time-PCR (RT-qPCR) procedure. PB, peripheral blood.](jcp-22-074f2){#f2-jcp-22-074}

![The mechanism of Hedgehog (Hh) signal transduction. (A) In the resting state, Pached (PTCH)1/2 is expressed on the plasma membrane and acts to repress Smoothened (SMO) activity by preventing its expression and localization to the primary cilium. GLI2/3 transcription factors are within a complex, including SUFU, an inhibitor of Hh signaling. This complex promotes nonspecific phosphorylation of the C-terminus by GSK3β, CSI, and PKA, resulting in E3 ubiquitin ligase activity and subsequent partial proteosomal proteolysis to the C-terminal truncated repressor form. After translocation to the nucleus, the repressive form of GLI2 (GLI2-R) and GLI-3R potently inhibit the Hh transcriptional program. (B) Interaction of Hh ligand with PTCH promotes PTCH internalization and degradation and blocks the repression of SMO, causing its accumulation within the primary cilium. Active SMO in the primary cilium stabilizes the full-length forms of GLI2 (GLI2-A) and GLI3 (GLI3-A) and accentuates the effect of other positive regulators of Hh signaling, including serine threonine kinase 36 (STK36) and kinesin family member 7 (KIF7), which may be involved in translocation of GLI into the primary cilium. After translocation to the nucleus, GLI2-A potently activates transcription of downstream Hh targets, including GLI1 and PTCH1, and influences chromatin conformation, apoptosis, cell cycle activity, and differentiation (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3705708/figure/F1/>).](jcp-22-074f3){#f3-jcp-22-074}

![The potential BCR-ABL1--dependent molecular mechanisms leading to chronic myeloid leukemia disease progression (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2898591/>). BAD, BCL2 antagonist of cell death; DNA-PKcs, DNA-dependent protein kinase, catalytic subunit; FOXO, fork head box O; IK6, Ikaros 6; miR-328, microRNA-328; MLH1, mutL homolog 1; PMS2, post meiotic segregation increased 2; RAD51, RecA homolog in *Escherichia coli*; RAD52, RAD52 homolog (*Saccharomyces cerevisiae*); Shh, Sonic Hh; wnt/β-catenin, wingless-int1/beta-catenin.](jcp-22-074f4){#f4-jcp-22-074}

###### 

NCCN guidelines on chronic myelogenous leukemia

  Indication                                        Testing                                   Frequency
  ------------------------------------------------- ----------------------------------------- -------------------------------------
  At diagnosis before therapy                       RT-qPCR and BM cytogenetics               
  If BM is not feasible, FISH on PB is acceptable                                             
  During therapy                                    RT-qPCR                                   Every 3 months
  BM cytogenetics                                   BM cytogenetics At 3, 12, and 18 months   
  After complete cytogenetic response               ABL kinase domain mutation analysis       When initial response is inadequate
  RT-qPCR                                           Every 3--6 months                         
  BM cytogenetics to detect clonal evolution        As clinically indicated                   
  FISH is not recommended                                                                     
  Increasing levels of *BCR-ABL1* transcripts       Evaluate compliance                       As clinically indicated
  Repeat RT-qPCR in those with MMR                                                            
  BM cytogenetics in those without MMR                                                        
  Consider ABL kinase domain mutation analysis                                                

National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines) Chronic Myelogenous Leukemia version 3.2013 (section CML-A, page 15; <http://www.nccn.org/professionals/physician_gls/pdf/cml.pdf>). RT-qPCR, quantitative real time-PCR; BM, bone marrow; PB, peripheral blood; MMR, mismatch repair.

###### 

Relative frequencies of recently identified molecular abnormalities in chronic myelomonocytic leukemia

  Major class of genetic mutation         Classify               Gene       Frequency of mutation (%)
  --------------------------------------- ---------------------- ---------- ---------------------------
  Epigenetic control                      Histone modification   *ASXL1*    40
                                                                 *EZH2*     5--10
                                          DNA methylation        *TET2*     40--60
                                                                 *DNMT3A*   \<5
                                          BOTH                   *IDH1*     1
                                                                 *IDH2*     5--10
  Cytokine signaling                                             *JAK2*     5--10
                                                                 *NRAS*     10
                                                                 *KRAS*     5--10
                                                                 *NOTCH2*   \<5
                                                                 *FLT3*     \<5
  Pre-mRNA splicing                                              *SRSF2*    30--50
                                                                 *SF3B1*    5--10
                                                                 *U2AF1*    \<5
  Transcription and nucleosome assembly                          *RUNX1*    15
                                                                 *SETBP1*   5--10
  DNA damage                                                     *TP53*     1
